Back to Clinical Studies
TAME Trial: Testing Metformin for Longevity
Clinical Studies

TAME Trial: Testing Metformin for Longevity

Published on March 14, 2026
•
By Lifespan Team
•
0 views

Overview of the groundbreaking TAME trial investigating metformin as a potential anti-aging intervention.

TAME Trial: Testing Metformin for Longevity

The Targeting Aging with Metformin (TAME) trial is a landmark study investigating whether metformin, a common diabetes drug, can delay aging and age-related diseases in humans.

Study Design

  • Large-scale, double-blind, placebo-controlled trial

  • Participants: Adults aged 65-79 without diabetes

  • Duration: 6 years

  • Primary outcome: Time to first age-related disease

    Rationale

    Metformin has shown promise in:

  • Animal longevity studies

  • Observational human studies

  • Cellular aging research

    Potential Mechanisms

  • AMPK activation

  • Reduced inflammation

  • Improved mitochondrial function

  • Enhanced autophagy

    Significance

    If successful, TAME could establish the first FDA-approved anti-aging therapy.